UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000060140 |
|---|---|
| Receipt number | R000068779 |
| Scientific Title | A verification study of the test food intake on immune function, a randomized, double-blind, placebo-controlled, parallel study. |
| Date of disclosure of the study information | 2026/04/01 |
| Last modified on | 2025/12/19 17:09:43 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A verification study of the test food intake on immune function.
Acronym
A verification study of the test food intake on immune function.
Scientific Title
A verification study of the test food intake on immune function, a randomized, double-blind, placebo-controlled, parallel study.
Scientific Title:Acronym
A verification study of the test food intake on immune function.
Region
| Japan |
Condition
Condition
To verify the effects of consumption of the test food on immune function in healthy Japanese subjects.
Classification by specialty
| Medicine in general |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To verify the effects of consumption of the test food on immune function in healthy Japanese subjects.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Cold symptom score
Key secondary outcomes
Major immune marker
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Duration: 8 weeks
Test food: Tablet containing plant extract
Administration: Take 1 capsule per day.
Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day.
Interventions/Control_2
Duration: 8 weeks
Test food: Placebo tablet
Administration: Take 1 capsule per day
*Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Japanese
2. Men or women
3. Subjects aged 20 or more
4. Healthy subjects
5. Subjects who are judged as eligible to participate in study by the physician
Key exclusion criteria
1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Subjects who currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Subjects who take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily use
5. Subjects who currently taking medications (including herbal medicines) and supplements
6. Subjects who are allergic to medicines and/or the test food related products
7. Subjects who are pregnant, lactation, or planning to become pregnant
8. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
9. Subjects who are judged as ineligible to participate in the study by the physician
10. Subjects who have been vaccinated against influenza within three months
11. Subjects who suffer from COVID-19
Target sample size
22
Research contact person
Name of lead principal investigator
| 1st name | Hiroki |
| Middle name | |
| Last name | Goto |
Organization
Medical corporation Seiryukai group the Goto Clinic
Division name
Director
Zip code
493-0005
Address
170 Kisogawa-cho Satokomakinokata, Ichinomiya-shi, Aichi-ken, Japan.
TEL
0586-87-7800
info@oryza.co.jp
Public contact
Name of contact person
| 1st name | HIROSHI |
| Middle name | |
| Last name | SHIMODA |
Organization
Oryza Oil & Fat Chemical Co. Ltd.
Division name
R&D
Zip code
493-8001
Address
1 Numata, Kitagata-cho, Numata, Ichinomiya, Aichi
TEL
0586-86-5141
Homepage URL
kaihatsu@mri.biglobe.ne.jp
Sponsor or person
Institute
Oryza Oil & Fat Chemical Co. Ltd.
Institute
Department
Personal name
Funding Source
Organization
Oryza Oil & Fat Chemical Co.Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address
9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.
Tel
03-5793-3623
IRB@takara-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
オリザ油化株式会社（愛知県）
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 04 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2025 | Year | 11 | Month | 01 | Day |
Date of IRB
| 2025 | Year | 11 | Month | 13 | Day |
Anticipated trial start date
| 2025 | Year | 12 | Month | 01 | Day |
Last follow-up date
| 2026 | Year | 02 | Month | 15 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2025 | Year | 12 | Month | 19 | Day |
Last modified on
| 2025 | Year | 12 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068779
